The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Which patients with R/R MCL benefit from CAR-T therapy?

Sep 10, 2020

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Michael Wang, MD Anderson Cancer Center, Houston, US. We asked, Which patients with R/R MCL benefit from CAR-T therapy?

Which patients with R/R MCL benefit from CAR-T therapy?

Here, Michael Wang talks about mantle cell lymphoma (MCL) and the results of the ZUMA-2 clinical trial. Treatment for MCL has evolved from chemotherapy, through targeted therapy, to cell and immunotherapies. Patients with relapsed/refractory (R/R) disease following treatment with this last group of therapies are classified as high-risk.